WEY Wolfeye Resource Corp

Testing’s Critical Role in Stemming the Tide

Testing’s Critical Role in Stemming the Tide

NEW YORK, July 22, 2020 (GLOBE NEWSWIRE) -- via NetworkWire — LexaGene Holdings Inc. (TSXV: LXG) (OTCQB: LXXGF) today announces its placement in an editorial published by ("NNW"), one of 40+ brands in the (“IBN”), a multifaceted financial news and publishing company for private and public entities.

To view the full publication, “Breakthroughs and Advancements in Pathogen Detection Offer Hope as Virus Cases Surge,” visit:

Setting a new standard in testing, LexaGene Holdings Inc. (TSXV: LXG) (OTCQB: LXXGF) () has developed a unique pathogen detection instrument—a fully automated genetic analyzer used to rapidly identify multiple pathogens, bacteria, and viruses including COVID-19. LexaGene’s breakthrough technology is highly accurate, designed to be used at sample collection sites, and can deliver test results on 27 pathogens and/or antimicrobial resistance factors at once in about an hour. LexaGene is already working with the FDA on its submission plan for Emergency Use Authorization (EUA) for COVID-19 testing.

Testing is the first and foremost tool in the fight against the coronavirus. But with cases in the US and around the world skyrocketing, the need for faster, more accurate tests is urgent. Public health experts across the globe agree that early detection is paramount to controlling the spread of the disease. Fast, accurate testing allows for contact tracing and isolating infections to stop rampant spread, but the country is falling short on testing as demand for tests far outstrips supply and availability.

About LexaGene Holdings Inc.

LexaGene is a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers for on-site rapid testing in veterinary diagnostics, food safety and for use in open-access markets such as clinical research, agricultural testing and biodefense. End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, enter sample ID and press ‘go’. The LX Analyzer delivers excellent sensitivity, specificity, and breadth of detection and can return results in about 1 hour. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest.

About NetworkNewsWire

(“NNW”) is a financial news and content distribution company, one of 40+ brands within our (“IBN”), that provides: (1) access to a network of wire solutions via  to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit: 

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: 

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications:

NetworkNewsWire (NNW)

New York, New York



212.418.1217 Office

EN
22/07/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Wolfeye Resource Corp

 PRESS RELEASE

LexaGene Files for Chapter 7 Bankruptcy

LexaGene Files for Chapter 7 Bankruptcy BEVERLY, Mass., Feb. 24, 2023 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), announces that it has ceased operations, laid off its staff, and, together with its direct subsidiary LexaGene, Inc., and its indirect subsidiary Bionomics Diagnostics, Inc., filed a voluntary petition for relief under Chapter 7 of the U.S. Bankruptcy Code. The filing, which took place earlier today at the U.S. Bankruptcy Court for the District of Massachusetts, located in Boston, Massachusetts, will result in federal ...

 PRESS RELEASE

LexaGene Provides Update on BioPharma Sector

LexaGene Provides Update on BioPharma Sector BEVERLY, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- , (; ) (“LexaGene” or the “Company”), an innovative, molecular diagnostics company that has commercialized the for automated, genetic testing, is pleased to provide the following update on the Company’s efforts to have the MiQLab System adopted for routine testing during the manufacturing of biologics. Dr. Jack Regan, CEO and Founder of LexaGene commented, “We continue to work with both of our biopharma customers - a more traditional biopharma company with a market cap that is >$100B and a l...

 PRESS RELEASE

LexaGene’s MiQLab System Detects Mycoplasma at Minute Levels, Rousing ...

LexaGene’s MiQLab System Detects Mycoplasma at Minute Levels, Rousing Additional Interest from BioPharma Customers BEVERLY, Mass., Jan. 18, 2023 (GLOBE NEWSWIRE) -- , (; ) (“LexaGene” or the “Company”), an innovative, molecular diagnostics company that has commercialized the for automated, genetic testing, is pleased to announce exciting news regarding the ability of the MiQLab System to detect Mycoplasma at minute levels. Dr. Jack Regan, CEO and Founder of LexaGene commented, “In the process of completing the follow-on feasibility study with one of our biopharma customers, I’m thrilled...

 PRESS RELEASE

BioPharma Engages LexaGene in Second Feasibility Study

BioPharma Engages LexaGene in Second Feasibility Study Cancels Plans to Reprice Meridian’s Warrants BEVERLY, Mass. , Dec. 16, 2022 (GLOBE NEWSWIRE) -- , (; ) (“LexaGene” or the “Company”), an innovative, molecular diagnostics company that has commercialized the for automated, genetic testing, is pleased to announce the large biopharma company (>$100B Market Cap) that previously purchased a MiQLab System has engaged LexaGene in a second statement of work (“SOW”) that builds off of the previously completed SOW. Dr. Jack Regan, LexaGene’s CEO and Founder commented, “In the biopharma indu...

 PRESS RELEASE

LexaGene Holdings Proposes to Amend Warrants Terms

LexaGene Holdings Proposes to Amend Warrants Terms BEVERLY, Mass., Dec. 07, 2022 (GLOBE NEWSWIRE) -- , (; ) (“LexaGene” or the “Company”), an innovative, molecular diagnostics company that has commercialized the for automated, genetic testing, announces that it intends to amend the exercise price of certain common share purchase warrants (the “Warrants”) originally issued on February 7 and February 18, 2022 to Meridian LGH Holdings, LLC and expiry five years after the date of issue. An aggregate of 18,500,000 Warrants were initially issued with an exercise price of CAD$0.45 per common s...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch